Glucotrack (GCTK) has completed its strategic business combination with Lōkahi Therapeutics, with Lōkahi becoming the operating and controlling entity of the combined company. This transaction effectively transforms Glucotrack into a public market platform for Lōkahi's healthcare asset identification and advancement model, with Lōkahi securityholders set to own approximately 90% of the combined entity.
Glucotrack (GCTK) has completed a reverse merger with Lōkahi Therapeutics, where Lōkahi effectively takes over the public company. This is a significant event for GCTK as it fundamentally changes the company's business model and ownership structure, with Lōkahi shareholders gaining approximately 90% of the combined entity. For existing GCTK shareholders, this represents substantial dilution and a shift from a continuous blood glucose monitoring company to a platform for Lōkahi's dual-engine healthcare asset model. The short-term implication is likely volatility as the market digests this transformation and the planned private placement financing. Long-term, the success of the combined entity will depend entirely on Lōkahi's ability to identify and advance healthcare assets. Traders should note the massive shift in control and business focus.